Literature DB >> 10435062

Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey.

F N Bennedbaek1, H Perrild, L Hegedüs.   

Abstract

BACKGROUND AND
OBJECTIVE: The optimum diagnostic and therapeutic strategy for the euthyroid patient with a solitary thyroid nodule is still a matter of debate. The aim was to assess the attitudes towards management of such patients in clinical centres throughout Europe by means of a questionnaire.
DESIGN: The questionnaire was circulated to all clinical members of the European Thyroid Association (ETA). A case report was followed by diagnostic investigations and choice of therapy in the index case (a 42-year old woman with a solitary 2 x 3 cm thyroid nodule and no clinical suspicion of malignancy). Eleven variations of the basic case report were proposed in order to evaluate how each alteration would affect management. MATERIAL: 151 members replied to the letter and 110 individuals from 20 countries completed the questionnaire (corresponding to approximately two-thirds of the clinical members of the ETA). They represented clinicians who had diagnosed and treated more than 50 (76%) or less than 50 (24%) patients with nodular thyroid disease within the previous 6 months.
RESULTS: Based on the index case, basal serum TSH was the routine choice of 99% and serum T4 and/or free T4 were included by 70% of the respondents. Almost 50% included determination of serum thyroid autoantibodies (TPOab: 47%, Tgab: 26%) and 43% measured serum calcitonin. Thyroid scintigraphy was used by 66% (99mTc: 86%, 123I: 10%, 131I: 4%), ultrasonography (US) by 80% (size: 75%, grey scale: 57%, Doppler: 33%). Scintigraphy in addition to US was used by 58%. Fine-needle aspiration biopsy (FNAB) was routinely used by 99% of the respondents, and performed under US-guidance by 42%. Based on the individually chosen diagnostic tests indicating a benign solitary thyroid nodule, a nonsurgical strategy was advocated by 77%. Despite controversies on L-T4 treatment this treatment was supported by more than 40% of the clinicians. Surgery was advocated by 23% and the preferred technique was hemithyroidectomy (70%). Clinical factors raising suspicion of thyroid malignancy (e.g. family history of thyroid cancer, history of external radiation, rapid nodule growth and a large nodule of 5 cm) lead the majority (70-91%; P < 0.000001) to disregard FNAB results and to choose a surgical strategy.
CONCLUSIONS: The favoured diagnostic strategy in the workup of patients with a solitary thyroid nodule include determinations of serum TSH combined with serum T4 and/or free T4 followed by FNAB and US together with scintigraphy. A nonsurgical strategy was favoured by the majority supporting the use of L-T4 as the first choice. In case of clinical factors raising the likelihood of malignancy, the majority recommended diagnostic thyroidectomy despite FNAB suggesting a benign condition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435062     DOI: 10.1046/j.1365-2265.1999.00663.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

1.  Management of nodular thyroid disease. The challenge remains identifying which palpable nodules are malignant.

Authors:  M K Jones
Journal:  BMJ       Date:  2001-08-11

2.  Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum.

Authors:  Alex Stagnaro-Green; Marcos Abalovich; Erik Alexander; Fereidoun Azizi; Jorge Mestman; Roberto Negro; Angelita Nixon; Elizabeth N Pearce; Offie P Soldin; Scott Sullivan; Wilmar Wiersinga
Journal:  Thyroid       Date:  2011-07-25       Impact factor: 6.568

3.  A Conservative Approach Is Reasonable in Patients with Non-Toxic Goitre: Results from an Observational Study during 30 Years.

Authors:  Johannes Järhult; Ramtin Vedad
Journal:  Eur Thyroid J       Date:  2014-10-15

4.  The management of thyroid nodules: a retrospective analysis of health insurance data.

Authors:  Romy Wienhold; Markus Scholz; J Rgen-Bernhard Adler; Christian G Nster; Ralf Paschke
Journal:  Dtsch Arztebl Int       Date:  2013-12-06       Impact factor: 5.594

Review 5.  Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy.

Authors:  Steen Joop Bonnema; Søren Fast; Laszlo Hegedüs
Journal:  Endocrine       Date:  2011-10-05       Impact factor: 3.633

Review 6.  Evaluation and management of the pediatric thyroid nodule.

Authors:  Jeremy T Guille; Adwoa Opoku-Boateng; Susan L Thibeault; Herbert Chen
Journal:  Oncologist       Date:  2014-12-05

7.  Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.

Authors:  A Giustina; T Mancini; P F Boscani; E de Menis; E degli Uberti; E Ghigo; E Martino; F Minuto; A Colao
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

8.  Combined use of fine-needle aspiration biopsy, MIBI scans and frozen section biopsy offers the best diagnostic accuracy in the assessment of the hypofunctioning solitary thyroid nodule.

Authors:  Luis Mauricio Hurtado-López; Sara Arellano-Montaño; Evelyn Migdalia Torres-Acosta; Felipe Rafael Zaldivar-Ramirez; Reyna Margarita Duarte-Torres; Patricia Alonso-De-Ruiz; Iván Martínez-Duncker; Carlos Martínez-Duncker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-06       Impact factor: 9.236

9.  TSH alone is not sufficient to exclude all patients with a functioning thyroid nodule from undergoing testing to exclude thyroid cancer.

Authors:  Luis-Mauricio Hurtado-López; Blanca-Estela Monroy-Lozano; Carlos Martínez-Duncker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-04       Impact factor: 9.236

Review 10.  Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature.

Authors:  Jacob Moalem; Insoo Suh; Quan-Yang Duh
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.